罗海彬

罗海彬，男，博士，中山大学药学院教授、博士生导师、副院长，国家重点研发计划首席科学家，广东省"珠江学者"特聘教授，国家自然科学基金来自优秀青年基金获得者，中国药学会-施维雅青年药物化学奖获得者，SCI期刊Chem Biol Drug Des、药学学报(英文版)、药学研究编委。罗博士，360百科1977年出生，胶钟裂业海传封衡1999年于厦门大学获学士学位; 2005年于尔需烧现电香港浸会大学获博士学位;2006年12月中山大学"百人计划"引进为药学院副教授;2011年12月晋升为教授，2012年被聘为药学院院长助理，2014年被聘为药学白鲜生欢还乙点院副院长，2015年获得国家自然科学基金优秀青年基金支持，2016年入选广东省"珠念担京江学者"特聘教授。兴劳振束关失项罗博士主要从事药物化学和结构生物学等方面的研究。多年来从事抗老年性痴呆、肺动脉高压、糖尿病、哮喘等药物靶标结构生物学和发现研究，重点具景站构英构建基于靶标磷酸二酯酶(PDE)的药物筛选体系，并进行相关的药物分子设计、有机合成和作用令队景笑机制研究。

• 中文名称 罗海彬
• 毕业院校 香港浸会大学
• 学位/学历 博士
• 专业方向 药物化学和结构生物学
• 职务 大学药学院副院长

人物经历

教育经历

• 1995.09-1999.07 论蛋副底验饭厦门大学化学系，学士
• 1999.09-2002.07 厦门大学化学系，硕士
• 2002.10来自-2005.12 香港浸会大学化学系，博士

工作经历

• 2005.12-2006.12 香港浸会大学化学系，博士后
• 全而白当肥庆干振2006.11-2011.12 中山大学药学院，"百人计划"引进，副教授，药物化学
• 2008.气经强周晶奏07-2008.10 弗吉尼亚大学医学院，访问学者
• 2009.06-2009.09 弗吉尼亚大学医学院，访问学者
• 2011.12-迄今 中山大学药学院，教授
• 2012.06-2014.04 中山大学药学院，院长助理
• 2012360百科.08-迄今 中山大学药学院，博导
• 2014.04-迄今 中山大学药学院，副院长

社会兼职

1. 中国化学会计算机化学艺殖祖今胡香析专业委员会委员
2. 广东省高性能计算协会常务理事
3. 广东省药物化学专业委员会副主话因演已江汉护富整思委兼秘书长
4. SCI期刊Chem Biol Dr红庆看考界翻想ug Des、药学学报(英文版)、药学研究编委

学术成果

科研项目

1. 国家重点研发计划高性能计算专项，基于E级计算的高性能生物医药软件系统的研制与应用，2017.07-2020.122.
2. 国家自然科来自学基金优秀青年基金项目:药物设计与发现，20360百科16.01-2018.12并我势伟两科答3.
3. 广东省"珠江学者"特聘教授项目，2016.10-2021.094.
4. 国家自然科学基金面上项目远互聚即危冷:新型抗肺动脉高压PDE5高选择性抑制剂的结构优化和分子机制研究，2016.01-2019.125.
5. 国家自然科学基金面引鲜上项目: 选择性识别磷酸二酯酶PDE9的嘧啶酮类衍生标容已今策评数少含优物:设计、合成与分子机制研究， 2013.01-2017.126.
6. 广东省自然科学基找远没线当金团队项目:基于靶标磷酸二酯酶结构的先导物筛选及其形应临床前研究，分题主径反计输封曾为业持，2011.10他贵独个争鸡命设屋复-2016.097.
7. 教继运响发般量象婷下边育部博士点基金: 磷酸二酯酶PDE9高选择性抑制剂的设计和构效关系研究，2014.01-2016.12

代表性论文

　　[1] Wu, D.W.; Zhang, T.H.; Chen, Y.; Huang, Y.; Geng, H.; Yu, Y.; Zhang, C留缺孔见氧派具袁别备., Lai, Z.W.; Wu, 六司养害Y.; Guo, X.; Chen, J. W.*; Luo, L.-B.* Discovery and Optimizatio况晚加令叶度牛务考n of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective an克粮d Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arteria封息煤倒叶甲证l Hypertension. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.7b00523.

　　[2] Huang, Y.; Liu, X.; Wu, D.; Tang, G.; Lai, Z.; Zheng, X. *; Yin. S. *; Luo, H.-B. * The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochem. 待定汉张陆十待员细显Pharmacol. 2017, 130, 51-59.

　　[3] Zhang, C.; Feng, L.J甲律数.; Huang, Y.; Wu, D.; Li, Z.; Zh见更令差小宽今ou, Q.; Wu, Y. *; Luo, H.-B.* Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optim乱画集妒劳曲ization, and Bioassay. J. Chem. Inf. Model. 2017, 57, 355-364.

　　[4] Cai, Y. H.; Guo, Y.; Li, Z.; Wu, D.; Li, X.; Zhang, H.; Yang, J.; Lu, H.; Sun, Z.; Luo, H.-B.; Yin, S.*; Wu, Y*. Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4. Eur. J. Med. Chem. 2016, 114, 134-140.

　　[5] Wu, Y.;* Cheng, J.; Wu, D.; Gu, Q.; Luo, Z.Y.; Luo, H.-B.* Palladium-catalyzed C–H bond carboxylation of acetanilides: an efficient usage of N,N-dimethyloxamic acid as the carboxylate source. Chem. Commun. 2016, 52, 1286-1289. PMID: 26616015

　　[6] Su, T.; Zhang, T.; Xie, S.; Yan, J.; Wu, Y.; Li, X.; Huang, L.*; Luo, H.-B. *. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease. Sci. Rep. 2016, 6:21826. PMID: 26911795

　　[7] Wu, Y.*; Sun, L.; Chen, Y.; Zhou, Q.; Huang, J.W.; Miao, H.; Luo, H.-B.* Palladium-Catalyzed Decarboxylative Acylation of N-Nitrosoanilines with α-Oxocarboxylic Acids. J. Org. Chem. 2016, 81(3):1244-1250. PMID: 26746881

　　[8] Li, Z.; Wu, Y., Feng, L.J.; Wu, R.*; Luo, H.-B.* Ab Initio QM/MM Study Shows a Highly Dissociated SN2 Hydrolysis mechanism for the cGMP-specific phosphodiesterase-5. J. Chem. Theory Comput. 2015, 10, 5448-5457.

　　[9] Huang, M.; Shao, Y.; Hou, J.; Cui, W.; Liang, B.; Huang, Y.; Li, Z.; Wu, Y.; Zhu, X.; Liu, P.; Wan, Y.*; Ke. H.*; Luo, H.-B.* Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor. Mol. Pharmacol. 2015, 88(5):836-845. PMID: 26316540

　　[10] Zhou, J.; Wu, R.*;Luo, H.-B.* Inhibition mechanism of SAHA in HDAC: a revisit. Phys. Chem. Chem. Phys. 2015, 17(44):29483-29488. PMID: 26497064

　　[11] Li, Z.; Lu, X.; Feng, L.J.; Gu, Y.; Li, X.; Wu, Y.;* Luo, H.-B.* Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Mol. Biosyst. 2015, 15, 115-125. PMID: 25328054.

　　[12] Shao, Y.X.; Huang, M.; Cui, W.; Feng, L.J.; Wu, Y.; Cai, Y.; Li, Z.; Zhu, X.; Liu, P.; Wan, Y.;* Ke, H.*; Luo, H.-B.* Discovery of a phosphodiesterase-9A inhibitor as a potential hypoglycemic agent. J. Med. Chem. 2014, 57, 10304-130313. PMID: 25432025.

　　[13] Shang, N.N.; Shao, Y.X.; Cai, Y.H.; Guan, M.; Huang, M.; Cui, W.; He, L.; Yu, Y.J.; Huang, L.; Li, Z.; Bu, X. Z.*; Ke, H.*; Luo, H.-B.* Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem. Pharmacol.2014, 89: 86-98. PMID:24565909

　　[14] Wu, Y.; Feng, L.J.; Lu, X.; Kwong, F.Y.*; Luo, H.-B.* Palladium-catalyzed oxidative C-H bond acylation of N-nitrosoanilines with toluene derivatives: a traceless approach to synthesize N-alkyl-2-aminobenzophenones. Chem. Commun. 2014, 50(97), 15352-15354. PMID: 25348462

　　[15] Zhou, J., Xie, H.; Liu, Z.;Luo, H.-B.*; Wu, R.* Structure-Function Analysis of the Conserved Tyrosine and Diverse π-Stacking among Class I Histone Deacetylases: A QM (DFT)/MM MD Study. J. Chem. Inf. Model. 2014, 54(11), 3162-3171. PMID: 25360823

　　[16] Liu, X.(#); Luo, H.-B.(#,并列第一作者); Huang, Y.Y.; Bao, J.M.; Tang, G.H.; Chen, Y.Y.; Wang, J.; Yin, S. Selaginpulvilins A-D, New phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella Pulvinata. Org. Lett. 2014, 162, 282-285. PMID: 24328835.

　　[17] Cheng, Z.B.; Lu, X.; Bao, J. M.; Han, Q.; Tang, G.H.; Gan, L.S.;Luo, H.-B.*; Yin, S.* (±)-Torreyunlignans A.D, Rare 8-9' Linked Neolignan Enantiomers as Phosphodiesterase-9A Inhibitors from Torreya yunnanensis. J. Nat. Prod. 2014, 77, 2651−2657.

　　[18] Cheng, Z.B.; Deng, Y.L.; Fan, C.Q.; Han, Q.H.; Lin, S.L.; Tang, G.H.; Luo, H.-B.*; Yin, S.* Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi. J. Nat. Prod. 2014, 77, 1928–1936. PMID: 25075977

　　[19] Lin, T.T.; Huang, Y.Y.; Tang, G.H.; Cheng, Z.B.; Liu, X.; Luo, H.-B.*; Yin, S.* Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica. J. Nat. Prod. 2014, 77: 955-962. PMID:24597921

　　[20] Liu, Y.N.; Huang, Y.Y.; Bao, J.M.; Cai, Y.H.; Guo, Y.Q.; Liu, S.N.; Luo, H.-B.*; Yin, S.* Natural phosphodiesterase-4 (PDE4) inhibitors from Crotalaria Ferruginea. Fitoterapi 2014, 94: 177-182. PMID:24594242

　　[21] Huang, Y.Y.; Li, Z.; Cai, Y.H.; Feng, L.J.; Wu, Y.; Li, X.; Luo, H.-B.* The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: A modeling study. J. Chem. Inf. Model. 2013, 53, 3044-3053. PMID: 24180640.

　　[22] Li, Z.; Cai, Y.H.; Cheng, Y.K.; Lu, X.; Shao, Y.X.; Li, X.; Liu, M.; Liu, P.; Luo, H.-B.* Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. J. Chem. Inf. Model. 2013,53, 972-981.PMID: 23517293.

　　[23] Zhao, P.; Chen, S.K.; Cai, Y.H.; Lu, X.; Li, Z.; Cheng, Y.K.; Zhang, C.; Hu, X.; He, X.*; Luo, H.-B.* The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay. Biochim Biophys Acta. 2013, 1834(10): 2089-2096. PMID: 23871879.

　　[24] Zhong, J.; Huang, Y.; Ding, W.; Wu, X.; Wan, J.*; Luo, H.-B.* Chemical constituents of Aloe barbadensis Miller and their inhibitory effects on phosphodiesterase-4D. Fitoterapia. 2013, 91:159-165. PMID: 24028970.

　　[25] Li, Y.P.; Weng, X.; Ning, F.X.; Ou, J.B.; Hou, J.Q.; Luo, H.-B.*; Li, D.; Huang, Z.S.; Huang, S.L.*; Gu, L.Q. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. J. Mol. Graph. Model. 2013, 41: 61-67. PMID: 23500628.

　　[26] Meng, F.; Hou, J.; Shao, Y. X.; Wu, P. Y.; Huang, M.; Zhu, X.; Cai, Y. H.; Li, Z.; Xu, J.; Liu, P. Q.; Luo, H.-B.*; Wan, Y.*; Ke, H*. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J. Med. Chem. 2012, 55(19): 8549-8558. PMID: 22985069.

　　[27] Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.B.; Ke, H.M.; Rehmann, H.; Taussig, R.; Brown, A.L.; Kim, M.K.; Beaven, M.A.; Burgin, A.B.; Manganiello, V.; Chung, J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148(3): 421-433. PMID: 22304913.

　　[28] Chen, S.-K.; Zhao, P.; Shao, Y.-X.; Li, Z.; Liu, M.; Zhang, C.X.; Liu, P.Q.; He, X.X.*; Luo, H.-B.*; Hu, X.P. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor. Bioorg. Med. Chem. Lett. 2012, 22: 3261–3264. PMID:22483586

　　[29] Zheng, X.H.; Shao, Y.X.; Li, Z.; Liu, M.; Bu, X.Z.; Luo, H.-B.*; Hu, X.P. Quantitative structure-retention relationship of curcumin and its analogues. J. Sep. Sci. 2012, 35: 505-512. PMID:22282411

　　[30] Shao, Y.X; Zhao, P.; Li, Z.; Liu, M.; Liu, P.Q.; Huang, M.; Luo, H.-B.* The molecular basis for the inhibition of human cytochrome P450 1A2 by oroxylin and wogonin. Eur. Biophys. J. 2012, 41: 297-306.

　　[31] Zheng, X.H.; Zhang, L.P.; Zhai, J; Chen, Y.Y.; Luo, H.-B.*; Hu, X.P.* The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Lett. 2012, 586: 55-59. PMID:22228220

　　[32] Fang, J.; Huang, D.; Zhao, W.; Ge, H.;Luo, H.-B.*; Xu, J.* A new protocol for predicting novel GSK-3 beta ATP competitive inhibitors. J. Chem. Inf. Model. 2011, 51: 1431-1438.

　　[33] Hou, J.; Xu, J.; Liu, M.; Zhao, R.; Luo, H.-B.*; Ke, H.* Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine. PLoS ONE 2011, 6. e18092.

　　[34] Liu, M.; Yuan, M.G.; Li, Z.; Cheng, Y.K.; Luo, H.-B.*; Hu, X.P.* Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I. Bioorg. Med. Chem. Lett. 2011, 21: 4243-4247.

　　[35] Chen, Y.Y.; Chen, G.W.; Luo, H.-B.* Molecular insight into the inhibitory mechanism of galangin towards human cytochrome P450 1A2. A modeling study. Lett. Drug Des. Discov. 2011, 8: 216-222.

　　[36] Luo, H.-B.; Zheng, H.-P.; et al. Crystal structure and molecular modeling study of N-carbamoylsarcosine amidase Ta0454 from Thermoplasma acidophilum. J. Struct. Biol.2010, 169: 304-311.

　　[37] He, L; He, F.; Bi, H.C.; Li, J.K.; Zeng, S.;Luo, H.-B.*; Huang, M. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg. Med. Chem. Lett.2010. 20: 6008-6012.

　　[38] Liu, M.; He, L.; Hu, X.P.; Liu, P.Q.; Luo, H.-B.* 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor. Bioorg. Med. Chem. Lett. 2010, 20: 7004-7010.

　　[39] Liu, M.; Yuan, M.G.; Luo, M.X.; Bu, X.Z.; Luo, H.-B.*; Hu, X.P.* Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis. Biophys. Chem. 2010, 147: 28-34.